Filtrer vos résultats
- 3
- 3
- 3
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFALeukemia Research, 2017, 54, pp.12-16. ⟨10.1016/j.leukres.2017.01.002⟩
Article dans une revue
hal-01557470v1
|
|||
Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemiaHematological Oncology, 2018, 36 (2), pp.422-428. ⟨10.1002/hon.2488⟩
Article dans une revue
hal-01698460v1
|
|||
|
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.Haematologica, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
Article dans une revue
hal-01984959v1
|